SCHEMBL25225472

SCHEMBL25225472

CCOc1ccc(F)c(-c2c(C(=O)O)sc3cc(F)ccc23)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCKDK O14874 1/20 0.47
▸ FFAR4 Q5NUL3 2/20 0.45
▸ FFAR1 O14842 1/20 0.45
▸ DHODH Q02127 2/20 0.41
▸ MEN1 O00255 1/20 0.39
▸ POLB P06746 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MCL1 Q07820 2/20 0.39
▸ ESR1 P03372 1/20 0.39
▸ EDNRB P24530 2/20 0.38
▸ MAPT P10636 2/20 0.38
▸ L3MBTL1 Q9Y468 1/20 0.38
▸ PPM1A P35813 1/20 0.38
▸ STING1 Q86WV6 1/20 0.37
▸ TBXAS1 P24557 1/20 0.37
▸ BCL2 P10415 1/20 0.36
▸ BCL2L1 Q07817 1/20 0.36
▸ BAD Q92934 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25205739 0.84 BCKDK (0.47) BCKDKMCL1ESR1STING1BCL2
SCHEMBL25575297 0.82 BCKDK (0.47) BCKDKDHODHMCL1ESR1MAPT
SCHEMBL25223907 0.81 BCKDK (0.48) BCKDKFFAR4DHODHMCL1ESR1
SCHEMBL25212935 0.80 BCKDK (0.47) BCKDKFFAR4DHODHMEN1POLB
SCHEMBL25218434 0.78 BCKDK (0.51) BCKDKMCL1ESR1MAPTSTING1
SCHEMBL31015941 0.78 BCKDK (0.58) BCKDKMCL1ESR1BCL2L1ALDH1A1
SCHEMBL25207336 0.78 BCKDK (0.58) BCKDKMCL1ESR1BCL2L1ALDH1A1
SCHEMBL25240228 0.77 BCKDK (0.49) BCKDKDHODHMEN1KMT2AMCL1
SCHEMBL25575337 0.77 BCKDK (0.49) BCKDKDHODHMEN1KMT2AMCL1
Ammonia Solution, Strong SCHEMBL25210526 0.76 BCKDK (0.48) BCKDKDHODHMEN1KMT2AMCL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12466803-B2 BCKDK inhibitors and/or degraders PFIZER INC. (US) 2025-11-11 — — US disclosed
WO-2023100061-A1 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE PFIZER INC. (US) 2023-06-08 — — WO disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 — — US disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 — — US disclosed
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS PFIZER INC. (US) 2023-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12466803-B2 BCKDK inhibitors and/or degraders BCKDK, KHK, PDK4 BCKDK 1/4885FFAR4 910/4885FFAR1 423/4885
US-20230167080-A1 BCKDK INHIBITORS AND/OR DEGRADERS BCKDK, KHK, PDK4 BCKDK 1/4885FFAR4 910/4885FFAR1 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback